A paper, made visible
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
- Available sources do not yet support a numeric visual.
What the available source describes
Study context is available. A quantitative result is not established here.
Study context 1 · source-backed descriptions
No supported numerical result is available for this comparison. No supported numeric visual is available.
Who or what was studied
patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes
What was examined
semaglutide
placebo
Outcome named in the source
heart failure-related symptoms and physical limitations
Inspect the source trail for this comparison
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
The mean change in the KCCQ-CSS was 13.7 points with semaglutide and 6.4 points with placebo (estimated difference, 7.3 points; 95% confidence interval [CI], 4.1 to 10.4; P<0.001),
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
CONCLUSIONS: Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure-related symptoms and physical limitations and greater weight loss than placebo at 1 year. (Funded by Novo Nordisk; STEP-HFpEF DM ClinicalTrials.gov number, NCT04916470.).
Study context 2 · source-backed descriptions
No supported numerical result is available for this comparison. No supported numeric visual is available.
Who or what was studied
patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes
What was examined
semaglutide
placebo
Outcome named in the source
weight loss
Inspect the source trail for this comparison
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
The mean percentage change in body weight was -9.8% with semaglutide and -3.4% with placebo (estimated difference, -6.4 percentage points; 95% CI, -7.6 to -5.2; P<0.001).
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
CONCLUSIONS: Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure-related symptoms and physical limitations and greater weight loss than placebo at 1 year. (Funded by Novo Nordisk; STEP-HFpEF DM ClinicalTrials.gov number, NCT04916470.).
Study context 3 · source-backed descriptions
No supported numerical result is available for this comparison. No supported numeric visual is available.
Who or what was studied
patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes
What was examined
semaglutide
placebo
Outcome named in the source
serious adverse events
Inspect the source trail for this comparison
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
Serious adverse events were reported in 55 participants (17.7%) in the semaglutide group and 88 (28.8%) in the placebo group.
- Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
CONCLUSIONS: Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure-related symptoms and physical limitations and greater weight loss than placebo at 1 year. (Funded by Novo Nordisk; STEP-HFpEF DM ClinicalTrials.gov number, NCT04916470.).